Loring Wolcott & Coolidge Fiduciary Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-300	Closed	-$2.26K	–	654
2023 Q2	$2.26K	Hold	300	–	–	﹤0.01%	609
2023 Q1	$2.65K	Buy	+300	New	+$2.97K	﹤0.01%	564
2019 Q1	–	Sell	-300	Closed	-$5K	–	758
2018 Q4	$5K	Hold	300	–	–	﹤0.01%	602
2018 Q3	$6K	Sell	300 -300	-50%	-$6.96K	﹤0.01%	561
2018 Q2	$15K	Hold	600	–	–	﹤0.01%	526
2018 Q1	$10K	Hold	600	–	–	﹤0.01%	583
2017 Q4	$11K	Sell	600 -510	-46%	-$7.67K	﹤0.01%	565
2017 Q3	$20K	Buy	1,110 +390	+54%	+$8.78K	﹤0.01%	509
2017 Q2	$23K	Sell	720 -130	-15%	-$4.02K	﹤0.01%	482
2017 Q1	$27K	Hold	850	–	–	﹤0.01%	471
2016 Q4	$31K	Hold	850	–	–	﹤0.01%	438
2016 Q3	$39K	Hold	850	–	–	﹤0.01%	420
2016 Q2	$43K	Sell	850 -550	-39%	-$29.3K	﹤0.01%	409
2016 Q1	$75K	Hold	1,400	–	–	﹤0.01%	341
2015 Q4	$92K	Buy	1,400 +550	+65%	+$34K	﹤0.01%	348
2015 Q3	$50K	Hold	850	–	–	﹤0.01%	417
2015 Q2	$50K	Hold	850	–	–	﹤0.01%	417
2015 Q1	$53K	Hold	850	–	–	﹤0.01%	426
2014 Q4	$49K	Hold	850	–	–	﹤0.01%	428
2014 Q3	$46K	Sell	850 -1,000	-54%	-$53K	﹤0.01%	423
2014 Q2	$97K	Sell	1,850 -8,215	-82%	-$420K	﹤0.01%	361
2014 Q1	$532K	Buy	10,065 +250	+3%	+$11.6K	0.01%	186
2013 Q4	$393K	Hold	9,815	–	–	0.01%	204
2013 Q3	$371K	Sell	9,815 -1,435	-13%	-$56K	0.01%	201
2013 Q2	$441K	Buy	+11,250	New	+$438K	0.01%	200

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's TEVA Position: Q3 2023 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Teva Pharmaceuticals (TEVA) in Q3 2023, closing a stake of 300 shares — an estimated $2.26K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in TEVA in Q2 2013 and held it in 25 quarters. The position peaked at $532K in Q1 2014. 435 funds tracked by Wall St. Rank hold TEVA as of Q3 2023.

Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Teva Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Loring Wolcott & Coolidge Fiduciary Advisors sold 300 Teva Pharmaceuticals shares in Q3 2023, an estimated $2.26K.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 25 quarters.
Loring Wolcott & Coolidge Fiduciary Advisors's Teva Pharmaceuticals position peaked at $532K in Q1 2014.
435 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2023.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q3 2023, filed 3 Nov 2023.